Endometrial Ablation in India and UAE | Complete Patient Guide

• ELIGIBLE PATIENTS:

• Women with heavy menstrual bleeding (HMB) confirmed by pictorial blood loss assessment chart (PBAC score >100) or objective measurement

• Patients who have completed their family (the procedure renders future pregnancy high-risk and is not recommended for those desiring future fertility)

• Women who have failed or are intolerant of first-line medical therapies (tranexamic acid, NSAIDs, LNG-IUS, combined hormonal contraception)

• Age typically 35–55 years; premenopausal or perimenopausal women

• Uterine cavity length ≤10 cm (device-specific eligibility criteria apply)

• Women with submucous fibroids <3 cm who are otherwise appropriate candidates (evaluated case-by-case)

• REQUIRED PRE-PROCEDURAL DIAGNOSTICS:

• Transvaginal ultrasound (TVUS): uterine size, cavity shape, fibroid mapping, endometrial thickness

• Saline infusion sonohysterography (SIS) or diagnostic hysteroscopy: cavity assessment for polyps, synechiae, or structural abnormality

• Endometrial biopsy (Pipelle or hysteroscopic-directed): mandatory to exclude endometrial hyperplasia (atypical or otherwise) and carcinoma

• Full blood count (FBC): assess iron-deficiency anaemia severity

• Coagulation screen: exclude inherited bleeding disorders (e.g., von Willebrand disease)

• Pregnancy test (mandatory on day of procedure)

• Cervical screening (Pap smear / HPV co-test): must be up to date

• Pre-anaesthetic assessment: ECG, basic metabolic panel if general anaesthesia planned

• CONTRAINDICATIONS (ABSOLUTE):

• Active or suspected endometrial, cervical, or uterine malignancy

• Desire for future pregnancy

• Active pelvic inflammatory disease (PID) or genital tract infection

• Uterine anomalies precluding device placement (e.g., bicornuate uterus, significant intrauterine adhesions)

• Prior classical (vertical) uterine incision or transmural myomectomy (risk of uterine rupture with thermal energy devices)

• Endometrial hyperplasia with atypia

• RELATIVE CONTRAINDICATIONS:

• Submucous fibroids >3 cm or those significantly distorting the cavity

• Uterine cavity >10 cm (device-specific)

• Concomitant adenomyosis (may reduce long-term efficacy; hysterectomy may be more appropriate)

• Postmenopausal status with unexplained bleeding (requires malignancy exclusion first)

FIRST-GENERATION TECHNIQUES (Resectoscopic — largely superseded but still used for complex cases):

• Transcervical Resection of the Endometrium (TCRE): A monopolar or bipolar resectoscope with a wire loop electrode removes the endometrium and superficial myometrium under direct hysteroscopic vision. Requires general or regional anaesthesia, distension media management, and advanced operative hysteroscopy skills. Best suited for cases with intracavitary pathology requiring simultaneous resection (e.g., submucous fibroids Type 0–1, polyps). Risk of fluid overload (monopolar), uterine perforation, and longer operative time.

• Rollerball / Rollerbarrel Ablation: Electrosurgical coagulation of the endometrium using a ball electrode. Often combined with TCRE for fundal and cornual treatment.

• Nd:YAG Laser Ablation: Historical gold standard; replaced by safer energy modalities.

SECOND-GENERATION TECHNIQUES (Global Endometrial Ablation / GEA — Current Standard of Care):

• NovaSure Radiofrequency Ablation (RFA): The most widely used GEA device globally. A bipolar gold mesh array is deployed within the uterine cavity, conforming to the cavity shape. Impedance-controlled radiofrequency energy is delivered for approximately 90 seconds, desiccating the endometrium to a depth of 4–5 mm. Requires no pre-operative endometrial thinning. Amenorrhoea rates of 40–50%; satisfaction rates >80% at 12 months. Minimal fluid absorption risk.

• Thermachoice / Cavaterm Balloon Therapy: A silicone balloon catheter is inserted transcervically, filled with dextrose solution, and heated to 87°C for 8 minutes. The thermal energy ablates the endometrial surface. Suitable for cavities 4–10 cm. Well-established safety profile with over two decades of clinical data.

• Minerva Endometrial Ablation System: Uses a plasma energy array within a conformable silicone membrane to deliver energy uniformly, including to the cornual regions. Proprietary technology enabling ablation without pre-operative thinning; real-time impedance monitoring.

• Her Option Cryoablation: Employs two freeze-thaw cycles using a cryoprobe inserted into each uterine cornu. Ice ball formation destroys the endometrium via cellular necrosis. Suitable for patients who cannot tolerate heat-based energy. Requires ultrasound monitoring intra-procedurally.

• Microwave Endometrial Ablation (MEA / Microsulis): A 9.2 GHz microwave probe is advanced to the fundus and withdrawn slowly, delivering controlled microwave energy. Real-time temperature monitoring at the uterine serosa; treatment time approximately 3–5 minutes. Particularly effective for irregular cavities.

• ThermaBlate EAS: A single-use balloon system with a ceramic heating element delivering dry heat; emerging technology with comparable efficacy to established balloon systems.

ADVANCED & COMBINED APPROACHES:

• Hysteroscopic Myomectomy + GEA: For patients with submucous fibroids (FIGO Type 0–2) coexisting with HMB, bipolar resectoscopic myomectomy (using systems such as Truclear or MyoSure tissue removal) is performed first, followed by GEA in the same operative session.

• Office-Based / Outpatient Ablation: Increasingly, NovaSure and Minerva procedures are being performed in an office or clinic setting under local cervical block (paracervical block) plus oral analgesics and anxiolytics, avoiding general anaesthesia entirely. This is available at select GAF Healthcare partner hospitals in both India and the UAE.

• Robotic-Assisted Hysteroscopic Guidance: Emerging platforms integrating robotic precision with hysteroscopic access for complex cavity management, available at premium centres.

PHASE 1 — PRE-ARRIVAL & TELEMEDICINE CONSULTATION (2–4 weeks before travel):

• Step 1: Submit medical records to GAF Healthcare's clinical team (gynaecology specialist review within 48 hours). Documents required: recent TVUS or pelvic MRI report, endometrial biopsy histology, blood results, menstrual history, and current medications.

• Step 2: Virtual consultation with the treating gynaecologist to confirm candidacy, select the appropriate ablation technique, and obtain an itemised cost estimate.

• Step 3: GAF Healthcare initiates e-Medical Visa application (India) or entry visa facilitation (UAE). Visa approval typically takes 3–5 business days for India e-Medical Visa.

• Step 4: Pre-operative hormonal endometrial thinning (if required by chosen technique): GnRH analogue (e.g., leuprolide acetate 3.75 mg IM, single dose) or danazol 200 mg twice daily for 4–6 weeks. NovaSure and Minerva do NOT require pre-thinning.

PHASE 2 — ARRIVAL & PRE-OPERATIVE ASSESSMENT (Day 0–1):

• Step 5: GAF Healthcare airport transfer to partner hospital or affiliated hotel.

• Step 6: In-person pre-operative consultation, repeat transvaginal ultrasound if interval imaging required, anaesthetic review, and written informed consent.

• Step 7: Pre-operative fasting (minimum 6 hours for solids, 2 hours for clear fluids if general anaesthesia planned). Cervical priming with misoprostol 400 mcg vaginally 2–4 hours before procedure facilitates transcervical access.

PHASE 3 — THE PROCEDURE (Day 1, typically morning):

• Step 8: Patient admitted to day-surgery unit. IV cannula sited, baseline observations, beta-hCG pregnancy test confirmed negative.

• Step 9: Anaesthesia administered — local/paracervical block with IV conscious sedation (midazolam + fentanyl), or brief propofol general anaesthetic (10–15 minutes).

• Step 10: Cervix dilated to Hegar 8–9. Diagnostic hysteroscopy performed to confirm cavity morphology and exclude unexpected pathology.

• Step 11: Chosen ablation device deployed (e.g., NovaSure array inserted, cavity width measured, suction activated, RF energy delivered for ~90 seconds). Total operative time: 15–30 minutes.

• Step 12: Recovery room observation for 1–2 hours. Oral analgesia (ibuprofen 400 mg or paracetamol 1 g) administered. Light diet and fluids commenced as tolerated.

PHASE 4 — IMMEDIATE POST-OPERATIVE PERIOD (Day 1–3):

• Step 13: Majority of patients discharged same day (day-case). Overnight stay offered if patient preference or anaesthetic considerations indicate.

• Step 14: Expected symptoms: mild-to-moderate uterine cramping (similar to period pain) for 24–72 hours, watery or blood-tinged vaginal discharge for 2–4 weeks. NSAIDs (ibuprofen 400 mg three times daily with food) recommended for the first 48–72 hours.

• Step 15: Activity guidance: rest on day of procedure; light activities resumable Day 2; avoid intercourse, tampons, and swimming for minimum 4 weeks.

PHASE 5 — RECOVERY MILESTONES & FIT-TO-FLY ASSESSMENT (Week 1–2):

• Step 16 (Day 5–7): In-person or telemedicine wound review with GAF Healthcare clinical coordinator. Confirm absence of infection, haematometra, or excessive pain.

• Step 17 (Day 7–10): Most patients are cleared for short-haul flights. Long-haul international travel (>4 hours) is recommended no earlier than Day 14 post-procedure.

• Step 18 (Week 2): Fit-to-fly letter issued by treating gynaecologist. Patient departs with discharge summary, histology reports, and next-steps plan.

PHASE 6 — LONG-TERM FOLLOW-UP (Month 1–12):

• Step 19 (6-week post-op): Telemedicine consultation with treating team via GAF Healthcare portal. Assessment of menstrual pattern change.

• Step 20 (3 months): Initial efficacy assessment — amenorrhoea, hypomenorrhoea, or eumenorrhoea documented. Haemoglobin re-checked.

• Step 21 (12 months): Formal outcome assessment. ~40–50% of patients achieve amenorrhoea; ~80–90% report clinically significant reduction in bleeding. ~5–10% may require repeat ablation or hysterectomy within 5 years.